CoChat

Zolpidem and Rebound Insomnia - A Double-Blind, Controlled Polysomnographic Study in Chronic Insomniac Patients

Monti, J., Attali, P., Monti, D., Zipfel, A., de la Giclais, B., Morselli, P. · 1994 · Pharmacopsychiatry
Cited by 92

The DOI matches its Crossref record.

Abstract

In a parallel-group, placebo-controlled, polysomnography study with randomization, the possible occurrence of rebound insomnia was evaluated in 24 patients suffering from moderate to severe chronic insomnia and receiving either triazolam 0.5 mg, Zolpidem 10mg, or placebo. Treatment duration was 27 nights, followed by three placebo controlled withdrawal nights. Both drugs showed significant efficacy compared to placebo during the active treatment period. A trend toward tolerance was noted in the triazolam group but not in the Zolpidem one. The increase in total sleep time in the Zolpidem group was accompanied by an increase in the number of sleep cycles. When active treatment was discontinued, clear rebound insomnia was present in the triazolam group while it was not possible to observe any rebound in the placebo and Zolpidem groups. Subjective feelings of the patients, which were assessed by means of visual analog scales, correlated well with polysomnographic data. Our findings tend to indicate that, even after long-term treatment, Zolpidem does not induce rebound insomnia or daytime anxiety. Zusammenfassung In dieser plazebokontrollierten, in drei Behandlungsgruppen randomisierten polysomnographischen Studie wurde das Auftreten von Rebound-Schlafstörungen nach Behandlung mit entweder Triazolam 0.5 mg, Zolpidem 10 mg oder Plazebo an 24 mittel- bis schwer chronisch schlafgestörten Patienten untersucht. Die Behandlungdauer betrug 27 Nächte gefolgt von drei Entzugsnächten mit Plazebo-Behandlung. Beide aktive Behandlungen waren signifikant verschieden von Plazebo während der aktiven Behandlungsperiode. Tendenzen für Toleranzentwicklungen traten nur in der Triazolamgruppe auf, nicht jedoch in der Zolpidemgruppe. Der Anstieg der Gesamtschlafzeit in der Zolpidemgruppe war begleitet von einem Anstieg in der Anzahl von Schlafzyklen. Nach Entzug der aktiven Behandlung traten in der Triazolamgruppe eindeutige Reboundeffekte auf; keine derartigen Effekte waren in der Plazebogruppe zu beobachten. Das subjektive Empfinden der Patienten, erfaßt durch visuelle Analogskalen, korrelierte gut mit den polysomnographischen Daten. Unsere Beobachtungen weisen darauf hin, daß Zolpidem, selbst nach Langzeitbehandlung, weder Rebound-Schlafstörungen noch Tages-Angst induziert.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1055/s-2007-1014298

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Monti, J., Attali, P., Monti, D., Zipfel, A., de la Giclais, B., & Morselli, P.
Venue
Pharmacopsychiatry
Published
1994-07
Volume
27
Issue
04
Pages
166-175
ISSN
  • 0176-3679 (ISSN-L)
  • 1439-0795
OpenAlex
W2079328435
Cited by
92
References
0
FWCI
10.44
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.